<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506868</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-066-2</org_study_id>
    <nct_id>NCT02506868</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients</brief_title>
  <official_title>Multicenter Double-blind Randomized Parallel Comparative Study of Efficacy and Safety of BCD-066 (CJSC BIOCAD, Russia) and Aranesp (Amgen Europe B.V., Netherlands) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to prove equivalence of efficacy and safety of BCD-066 and
      Aranesp® in treatment of anemia in end-stage chronic kidney disease patients on dialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study CKD patients on dialysis previously treated by short-acting epoetins will
      switch to one of darbepoetin alfa products - BCD-066 (experimental arm) or Aranesp (active
      comparator) to maintain previously achieved target level of hemoglobin (100-120 g/l).

      Patients will be treated for 52 weeks. IV iron supplementation will be provided to maintain
      serum ferritin level above 500 µg/l according to KDIGO Anemia Guidelines (2012).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2015</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">January 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period</measure>
    <time_frame>Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number or Percentage of Patients Who Have Target Hemoglobin Concentration During Evaluation Period</measure>
    <time_frame>Weeks 21 to 24</time_frame>
    <description>Hb concentration between 100 and 120 g/l will be considered as target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Darbepoetin Alfa Dose During Evaluation Period</measure>
    <time_frame>Week 21 to Week 24</time_frame>
    <description>The outcome includes the mean weekly dose of Darbepoetin Alfa which was administered to the patients during the period from week 21 to week 24 (last 4 weeks of the main period of the study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or Percentage of Patients With Need for Blood Transfusions</measure>
    <time_frame>Weeks 1 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or Percentage of Patients With Need for 'Dose Titration' at the Beginning of the Study</measure>
    <time_frame>Weeks 1 to 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hemoglobin Level During Evaluation Period</measure>
    <time_frame>Week 24</time_frame>
    <description>The outcome includes the mean hemoglobin level which was registered in the patients during the last 4 weeks of the main period of the study (period from week 21 to week 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or Percentage of Patients With Hemoglobin Level Between 90 and 100 g/l</measure>
    <time_frame>Weeks 21 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level Dynamics</measure>
    <time_frame>Weeks 1 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Darbepoetin Alfa Dose During the Whole Study</measure>
    <time_frame>Week 24</time_frame>
    <description>The outcome includes the mean Darbepoetin Alfa Dose During the Whole Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hemoglobin Level During the Whole Study (24 Week)</measure>
    <time_frame>Week 24</time_frame>
    <description>The outcome includes the measuere of Mean Hemoglobin Level During the Whole Study (during the study period from week 1 to week 24 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hematocrit Level During the Whole Study</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With AE/SAE (AE/SAE Incidence)</measure>
    <time_frame>Weeks 1 to 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3-4 AE/SAE</measure>
    <time_frame>Weeks 1 to 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Withdrew From Study Due to AE/SAE</measure>
    <time_frame>Weeks 1 to 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Arterial and Venous Thrombotic Events</measure>
    <time_frame>Weeks 1 to 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or Percentage of Patients With Binding and/or Neutralizing Antibodies Against Darbepoetin Alfa</measure>
    <time_frame>Weeks 1 to 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>BCD-066</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aranesp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Weekly sc administration of darbepoetin alfa</description>
    <arm_group_label>Aranesp</arm_group_label>
    <arm_group_label>BCD-066</arm_group_label>
    <other_name>Aranesp</other_name>
    <other_name>BCD-066</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age between 18 and 75 years

          -  End-stage kidney disease

          -  Need for dialysis for at least 3 months before enrollment

          -  Need for at least 12 hours on standard dialysis procedure weekly

          -  Regular rHuEpo (epoetin alfa, epoetin beta, darbepoetin alfa) administration 1, 2 or 3
             times a week (stable dose, stable frequency) for at least 3 months before enrollment

          -  Target hemoglobin level (100-120 g/l) for at least 3 months before enrollment

          -  Effective dialysis (Kt/v≥1,2)

          -  TSAT ≥20%, Serum ferritin &gt;200 ng/ml

          -  Patients and their sexual partners with childbearing potential must implement reliable
             contraceptive measures during all the study treatment, starting 4 weeks prior to the
             administration of the first dose of investigational product until 4 weeks after the
             last dose of investigational product. This requirement does not apply to participants
             who have undergone surgical sterilization. Reliable contraceptive measures include two
             methods of contraception, including one barrier method

          -  Patients should be able to follow the Protocol procedures (according to Investigator's
             assessment)

        Exclusion Criteria:

          -  Any other causes of anemia except for renal anemia, including folate and B12
             deficiency, chronic blood loss, aluminium intoxication, sickle-cell anemia, chronic
             disease anemia (CRP above 20 mg/l), refractory anemia with blast cells in peripheral
             blood

          -  Lupus nephritis of kidney disease due to systemic vasculitis

          -  Platelet count below 100х10^9 cells/l

          -  Hemoglobin above 120 g/l or below 100 g/l

          -  Scheduled kidney transplant during study participation period

          -  Binding/neutralizing antibodies against erythropoetin/darbepoetin

          -  History of severe allergic reactions

          -  Vaccination less than 8 weeks before enrollment

          -  Liver cirrhosis with portal hypertension and/or splenomegaly and/or ascitis

          -  HIV infection, active HBV, HCV

          -  ALT, AST level above 3x ULN

          -  Bone marrow fibrosis

          -  Congestive heart failure (Grade IV NYHA)

          -  Resistant arterial hypertension

          -  Unstable angina

          -  Hemoglobinopathy, MDS, hematologic malignancy

          -  PRCA

          -  Severe secondary hyperparathyroidism (PTH &gt; 9x ULN)

          -  GI bleeding history

          -  Thrombotic events history (myocardial infarction, stroke, TIA, DVT, PATE) less than 6
             months before enrollment

          -  Acute hemolysis history

          -  Seizures, including epilepsy

          -  Major surgery in less than 1 month before enrollment

          -  Blood transfusions in less than 3 months before enrollment

          -  Acute inflammatory diseases or exacerbations of chronic inflammation including septic
             of aseptic inflammation foci

          -  Severe psychiatric disorders

          -  History of malignancy, excluding appropriately treated basal cell carcinoma or
             cervical carcinoma in situ

          -  Alcohol or drug abuse

          -  Hypersensitivity to darbepoetin alfa of any components of study drugs

          -  Simultaneous participation in other trials or in less than 3 months before enrollment

          -  Pregnancy of breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrey Biryulin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Biocad</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Josaphat Belgorod Regional Clinical Hospital</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alyans Biomedical - Ural'skaya gruppa</name>
      <address>
        <city>Izhevsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaluga Region Hospital</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care Kuban</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEFROS Ltd, Medical Centre</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centr Dializa Ltd</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #24</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs&quot;, Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.I.Pirogov City Clinical Hospital #1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Clinical Centre, JSC Russian Railways</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nefrolayn-Novosibirsk Ltd</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Radiological Research Center, Ministry of Health and Social Development of the Russian Federation, Urology and Interventional Radiology Research Institute</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.N. Kabanov City Clinical Hospital #1</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omsk Regional Clinical Hospital</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.A. Baranov Republican Hospital of Ministry of Health republic Karelia</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital, Saratov</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Mariin Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #40, Kurortny district</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nikolaevskaya Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B.Braun Avitum Russland Clinics Ltd.</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centr Dializa Sankt-Peterburg Ltd</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #15</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical University named after I.I Mechnikov under the Ministry of Public Health of the Russian Federation</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg I.I. Dzhanelidze Research Institute of Emergency Medicine</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Holy Great Martyr Elizabeth City Hospital #2</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tula Regional Hospital</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Nephrocare Ltd - Dialysis Centre #2, Ul'yanovsk</name>
      <address>
        <city>Ul'yanovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Volgograd Region Uronephrology Centre</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <results_first_submitted>June 7, 2018</results_first_submitted>
  <results_first_submitted_qc>May 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2019</results_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>darbepoetin alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-066</title>
          <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
        </group>
        <group group_id="P2">
          <title>Aranesp</title>
          <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Period of Study (24 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>mITT Population</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="97">One patient from Aranesp group was excluded prior to the first administration</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Additional Period of Study (Until 52W)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp. One patient from Aranesp group was excluded prior to the first administration.</population>
      <group_list>
        <group group_id="B1">
          <title>BCD-066</title>
          <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
Darbepoetin alfa: weekly sc administration of darbepoetin alfa</description>
        </group>
        <group group_id="B2">
          <title>Aranesp</title>
          <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
Darbepoetin alfa: weekly sc administration of darbepoetin alfa</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="195"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>two population: mITT and Per protocol</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>mITT population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="45" upper_limit="66"/>
                    <measurement group_id="B2" value="56" lower_limit="46" upper_limit="63"/>
                    <measurement group_id="B3" value="57" lower_limit="46" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" lower_limit="45" upper_limit="63"/>
                    <measurement group_id="B2" value="56" lower_limit="46" upper_limit="62"/>
                    <measurement group_id="B3" value="56.5" lower_limit="46" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Two population: mITT and Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>mITT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Two population: mITT and Per protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>mITT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period</title>
        <time_frame>Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period</title>
          <units>gram per liter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.695" spread="10.941"/>
                    <measurement group_id="O2" value="4.641" spread="8.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number or Percentage of Patients Who Have Target Hemoglobin Concentration During Evaluation Period</title>
        <description>Hb concentration between 100 and 120 g/l will be considered as target</description>
        <time_frame>Weeks 21 to 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number or Percentage of Patients Who Have Target Hemoglobin Concentration During Evaluation Period</title>
          <description>Hb concentration between 100 and 120 g/l will be considered as target</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Darbepoetin Alfa Dose During Evaluation Period</title>
        <description>The outcome includes the mean weekly dose of Darbepoetin Alfa which was administered to the patients during the period from week 21 to week 24 (last 4 weeks of the main period of the study)</description>
        <time_frame>Week 21 to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Darbepoetin Alfa Dose During Evaluation Period</title>
          <description>The outcome includes the mean weekly dose of Darbepoetin Alfa which was administered to the patients during the period from week 21 to week 24 (last 4 weeks of the main period of the study)</description>
          <units>micrograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.779" spread="10.858"/>
                    <measurement group_id="O2" value="20.982" spread="10.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number or Percentage of Patients With Need for Blood Transfusions</title>
        <time_frame>Weeks 1 to 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number or Percentage of Patients With Need for Blood Transfusions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number or Percentage of Patients With Need for 'Dose Titration' at the Beginning of the Study</title>
        <time_frame>Weeks 1 to 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number or Percentage of Patients With Need for 'Dose Titration' at the Beginning of the Study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hemoglobin Level During Evaluation Period</title>
        <description>The outcome includes the mean hemoglobin level which was registered in the patients during the last 4 weeks of the main period of the study (period from week 21 to week 24)</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hemoglobin Level During Evaluation Period</title>
          <description>The outcome includes the mean hemoglobin level which was registered in the patients during the last 4 weeks of the main period of the study (period from week 21 to week 24)</description>
          <units>gram per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.054" spread="9.222"/>
                    <measurement group_id="O2" value="115.277" spread="7.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number or Percentage of Patients With Hemoglobin Level Between 90 and 100 g/l</title>
        <time_frame>Weeks 21 to 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number or Percentage of Patients With Hemoglobin Level Between 90 and 100 g/l</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level Dynamics</title>
        <time_frame>Weeks 1 to 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level Dynamics</title>
          <units>gram per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.155" spread="8.713"/>
                    <measurement group_id="O2" value="112.68" spread="8.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.831" spread="9.332"/>
                    <measurement group_id="O2" value="113.619" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.802" spread="8.962"/>
                    <measurement group_id="O2" value="115.378" spread="9.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.686" spread="9.416"/>
                    <measurement group_id="O2" value="116.533" spread="10.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.279" spread="10.327"/>
                    <measurement group_id="O2" value="116.846" spread="9.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.520" spread="10.317"/>
                    <measurement group_id="O2" value="116.878" spread="10.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.326" spread="11.646"/>
                    <measurement group_id="O2" value="115.322" spread="9.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.80" spread="10.61"/>
                    <measurement group_id="O2" value="116.528" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.593" spread="10.951"/>
                    <measurement group_id="O2" value="115.966" spread="9.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.372" spread="10.619"/>
                    <measurement group_id="O2" value="115.467" spread="8.656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.247" spread="9.645"/>
                    <measurement group_id="O2" value="114.582" spread="9.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.174" spread="9.604"/>
                    <measurement group_id="O2" value="115.444" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Darbepoetin Alfa Dose During the Whole Study</title>
        <description>The outcome includes the mean Darbepoetin Alfa Dose During the Whole Study</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Darbepoetin Alfa Dose During the Whole Study</title>
          <description>The outcome includes the mean Darbepoetin Alfa Dose During the Whole Study</description>
          <units>micrograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.625" spread="10.637"/>
                    <measurement group_id="O2" value="22.449" spread="11.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hemoglobin Level During the Whole Study (24 Week)</title>
        <description>The outcome includes the measuere of Mean Hemoglobin Level During the Whole Study (during the study period from week 1 to week 24 week)</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hemoglobin Level During the Whole Study (24 Week)</title>
          <description>The outcome includes the measuere of Mean Hemoglobin Level During the Whole Study (during the study period from week 1 to week 24 week)</description>
          <units>gram per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.394" spread="6.376"/>
                    <measurement group_id="O2" value="115.434" spread="6.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hematocrit Level During the Whole Study</title>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hematocrit Level During the Whole Study</title>
          <units>percentage of hematocrit (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.119" spread="2.194"/>
                    <measurement group_id="O2" value="35.173" spread="2.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With AE/SAE (AE/SAE Incidence)</title>
        <time_frame>Weeks 1 to 52</time_frame>
        <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks of main period and 28 week of additional period
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) or 24 weeks of main period and 28 week of additional period
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With AE/SAE (AE/SAE Incidence)</title>
          <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3-4 AE/SAE</title>
        <time_frame>Weeks 1 to 52</time_frame>
        <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks of main period and 28 week of additional period
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) or 24 weeks of main period and 28 week of additional period
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3-4 AE/SAE</title>
          <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Withdrew From Study Due to AE/SAE</title>
        <time_frame>Weeks 1 to 52</time_frame>
        <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks of main period and 28 week of additional period
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) or 24 weeks of main period and 28 week of additional period
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Withdrew From Study Due to AE/SAE</title>
          <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Arterial and Venous Thrombotic Events</title>
        <time_frame>Weeks 1 to 52</time_frame>
        <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 24 weeks of main period and 28 week of additional period
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) or 24 weeks of main period and 28 week of additional period
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Arterial and Venous Thrombotic Events</title>
          <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number or Percentage of Patients With Binding and/or Neutralizing Antibodies Against Darbepoetin Alfa</title>
        <time_frame>Weeks 1 to 52</time_frame>
        <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066</title>
            <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
          <group group_id="O2">
            <title>Aranesp</title>
            <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
          </group>
        </group_list>
        <measure>
          <title>Number or Percentage of Patients With Binding and/or Neutralizing Antibodies Against Darbepoetin Alfa</title>
          <population>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse event were collected during 1 year (24 weeks of main and 28 weeks of additional periods of study)</time_frame>
      <desc>The analysis included all patients who received at least one injection of BCD-066 or Aranesp - mITT population.
One patient from Aranesp group was excluded prior to the first administration.</desc>
      <group_list>
        <group group_id="E1">
          <title>BCD-066</title>
          <description>Patients in this arm received weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
        </group>
        <group group_id="E2">
          <title>Aranesp</title>
          <description>Patients in this arm received weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
Darbepoetin alfa: Weekly sc administration of darbepoetin alfa</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Paroxysmal atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction. Relapse of myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>peptic ulcer aggaravation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>acute gastoentrocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>chronic pancreatitis aggravation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Prepatellar hematoma of the left knee</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>acute gangrenous cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>chronic cholecystitis aggravation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dyscirculatory encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic circulatory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Increased blood pressure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Paget-Schroetter syndrome</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pulmonary thromboembolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute respiratory infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Increased blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yulia Linkova Medical Director</name_or_title>
      <organization>Biocad</organization>
      <phone>+7 (495) 992 66 28 ext 930</phone>
      <email>linkova@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

